NCT03777839

PET-FDG in Myocarditis

Evaluation of 18F-Fluorodeoxyglucose Positron Emission Tomography Imaging in Myocarditis

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 25 (actual)
• Sponsor: Montreal Heart Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates the diagnostic performance of 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) with rest perfusion imaging for the diagnosis of myocarditis. Patients with clinical suspicion of myocarditis will be recruited and undergo a rest myocardial perfusion scan and a FDG PET/CT scan following a myocardial suppression protocol.

Detailed description

Myocarditis is characterized by myocardial inflammation, which can lead to fibrosis and heart failure. FDG PET/CT, with appropriate suppression protocol including high-fat-low-carbohydrate diet, fasting, and IV heparin, can be use to detect myocardial inflammation. It is frequently used for the diagnosis of inflammation in cardiac sarcoidosis. After the initial inflammatory phase, inflammation resolves and fibrosis can seen. Resting perfusion imaging will allow identification of fibrosis. The combination of FDG PET/CT and rest perfusion imaging could allow detection of the various phases of myocarditis; inflammation and fibrosis.

Conditions

• Myocarditis
• Viral Myocarditis

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	FDG PET/CT	FDG PET CT imaging with rest perfusion imaging

Timeline

• Start date: 2018-11-20
• Primary completion: 2024-08-31
• Completion: 2024-08-31
• First posted: 2018-12-17
• Last updated: 2024-11-22

Locations

1 site across 1 country: Canada